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Dysfunction of NMDA receptor (NMDAR)-mediated transmission is supposed to contribute to the motor 
and non-motor symptoms of Parkinson’s Disease (PD), and to L-DOPA-induced dyskinesia. Besides 
the main agonist L-glutamate, two other amino acids in the atypical D-configuration, D-serine and 
D-aspartate, activate NMDARs. In the present work, we investigated the effect of dopamine depletion 
on D-amino acids metabolism in the brain of Mptp-lesioned Macaca mulatta, and in the serum and 
cerebrospinal fluid of PD patients. We found that MPTP treatment increases D-aspartate and D-serine 
in the monkey putamen while L-DOPA rescues both D-amino acids levels. Conversely, dopaminergic 
denervation is associated with selective D-serine reduction in the substantia nigra. Such decrease 
suggests that the beneficial effect of D-serine adjuvant therapy previously reported in PD patients 
may derive from the normalization of endogenous D-serine levels and consequent improvement of 
nigrostriatal hypoglutamatergic transmission at glycine binding site. We also found reduced D-serine 
concentration in the cerebrospinal fluid of L-DOPA-free PD patients. These results further confirm the 
existence of deep interaction between dopaminergic and glutamatergic neurotransmission in pD and 
disclose a possible direct influence of D-amino acids variations in the changes of NMDAR transmission 
occurring under dopamine denervation and L-DOPA therapy.
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Parkinson’s Disease (PD) is a chronic neurological disorder characterized by the degeneration of the dopamin-
ergic nigrostriatal pathway, which results in progressive motor dysfunction associated to non-motor symptoms, 
including apathy and dementia1,2. Pharmacological approaches to PD predominantly target the dopaminergic 
system, and dopamine (DA) replacement by its precursor L-3,4-dihydroxyphenylalanine (L-DOPA) remains the 
gold-standard treatment3. However, chronic L-DOPA exposure leads to motor side effects, including wearing-off 
and L-DOPA-induced dyskinesia4.
Progressive degeneration of the midbrain dopaminergic neurons results in an imbalance within cortico-basal 
ganglia circuit5 and is associated with altered glutamatergic transmission in both preclinical models and PD 
patients. There is indeed consistent agreement about the implication of dysfunctions of glutamatergic system in 
basal ganglia in PD pathophysiology, as well as in the motor disturbances associated with L-DOPA therapy2,6–11. 
Furthermore, the occurrence of altered stimulation of NMDA-type ionotropic glutamate receptors (NMDARs) 
is hypothesized to contribute to the molecular events underpinning excitation-mediated neuronal damage and 
apoptosis in PD brain12,13.
In the mammalian brain, besides the main excitatory amino acid L-glutamate (L-Glu), two amino acids in 
D configuration, D-serine (D-Ser) and D-aspartate (D-Asp), are known to influence NMDAR-mediated trans-
mission. In particular, D-Ser is known to stimulate the glycine-binding site of NMDARs14,15, while D-Asp binds 
to the glutamate site of this receptor subclass16. Conversely, their respective L-enantiomers, L-Ser and L-Asp, 
serve mainly as building blocks of proteins and metabolic intermediates17,18. In addition, L-Asp has long been 
recognized as a selective agonist for NMDARs, although its role as a neurotransmitter is still debated19. D-Ser is 
generated from L-Ser by the pyridoxal phosphate (PLP)-dependent enzyme serine racemase (SR)20,21, and its deg-
radation occurs through an oxidative deamination catalyzed by D-amino acid oxidase (DAAO)22,23. Conversely, 
the precise mechanism underlying the endogenous production of D-Asp is not yet understood, although it is 
well established that its degradation is catalyzed by D-aspartate oxidase (DDO) enzyme16,24. So far, only a few 
investigations have addressed the involvement of these D-amino acids in the dysfunctional glutamate transmis-
sion found in PD. In this regard, preclinical observations showed altered D-Ser concentrations in the brain of 
MPTP- and 6-OHDA-lesioned rodents25–27. A beneficial effect of D-Ser supplementation on motor and behav-
ioural symptoms of PD patients treated with L-DOPA has also been documented in a clinical trial28. Interestingly, 
this is in line with the therapeutic benefit displayed by another NMDAR enhancer, sarcosine (a type 1 glycine 
transporter inhibitor), on neuropsychiatric symptoms of PD29. On the other hand, observations in Ddo knockout 
(Ddo−/−) mice indicated that abnormally high D-Asp levels trigger age-dependent neuroinflammation and cell 
death in midbrain dopaminergic neurons30, as well as a precocious onset of L-DOPA-induced dyskinesia31.
In this work, by using a well-validated MPTP-lesioned primate model of PD, we first explored the conse-
quences of DA denervation and L-DOPA therapy upon D-Ser and D-Asp metabolism in the putamen, substantia 
nigra (SN) and medial frontal gyrus (MFG) of Macaca mulatta. Then, in order to assess the translational rele-
vance of preclinical studies in parkinsonian monkeys, we analyzed the concentration of these NMDAR-related 
modulators in the serum and cerebrospinal fluid (CSF) of PD patients.
Results
MPTP treatment in parkinsonian monkeys induces striatal increase in D-aspartate levels, 
which is normalized by L-DOPA therapy. In this study, we used MPTP-lesioned monkeys because, dif-
ferently to the commonly used 6-OHDA and MPTP-treated rodents, this primate PD model allows to better 
approximate the real pathological situation of PD patients32,33. Moreover, a subgroup of parkinsonian monkeys 
was chronically treated with L-DOPA in order to elicit dyskinetic motor disturbances and, thus, approximate the 
complications of L-DOPA treatment in patients.
We first analyzed the content of DA and its metabolite, 3,4-Dihydroxyphenylacetic acid (DOPAC), in the 
putamen of Macaca mulatta treated with MPTP or MPTP + L-DOPA. MPTP treatment induced nigro-striatal 
dopaminergic degeneration in monkeys, as indicated by dramatic decrease in striatal tyrosine hydroxylase (TH) 
expression (~75%), in both MPTP and MPTP + L-DOPA groups, when compared to controls (one-way ANOVA, 
F(2,12) = 32.62, p < 0.0001; Ctrl vs MPTP, p < 0.0001, Ctrl vs MPTP + L-DOPA, p < 0.0001, Fisher’s post-hoc com-
parison; Fig. 1a). In agreement with dopaminergic neuronal degeneration, HPLC analysis showed a significant 
effect of MPTP treatment on the levels of DA and its metabolite DOPAC (DA: F(2,12) = 105.2, P < 0.0001; DOPAC: 
F(2,12) = 27.03, P < 0.0001; Fig. 1b,c). In particular, we observed a severe depletion of both molecules in parkin-
sonian monkeys (Ctrl vs MPTP, mean ± SEM of pg/mg tissue; DA: 2754.0 ± 182.1 vs 141.0 ± 73.3, p < 0.0001; 
DOPAC: 411.0 ± 39.1 vs 58.2 ± 16.9, p < 0.0001; Fig. 1b,c). DA and DOPAC levels were still significantly reduced 
compared to control group, also after L-DOPA administration (Ctrl vs MPTP + L-DOPA, mean ± SEM of pg/mg 
tissue; DA: 2754.0 ± 182.1 vs 586.8 ± 131.2, p < 0.0001; DOPAC: 411.0 ± 39.1 vs 224.6 ± 40.5, p = 0.0022; Fig. 1b,c) 
as previously reported34,35. However, L-DOPA partially counteracted this reduction, as shown by significantly 
increased DA and DOPAC content in monkeys treated with MPTP + L-DOPA, compared to MPTP-lesioned 
animals (MPTP vs MPTP + L-DOPA, mean ± SEM of pg/mg tissue; DA: 141.0 ± 73.3 vs 586.8 ± 131.2, p = 0.0393; 
DOPAC: 58.2 ± 16.9 vs 224.6 ± 40.5, p = 0.0047; Fig. 1b,c) as previously reported34,35.
Then, we performed HPLC analyses in order to determine the striatal concentrations of amino acids involved 
in NMDAR modulation in MPTP-treated monkeys with or without L-DOPA administration, compared to naïve 
controls. Our data showed a significant main effect of MPTP treatment on striatal D-Asp levels (F(2,12) = 6.64, 
p = 0.0115; Fig. 1d). Notably, MPTP was able to increase D-Asp levels in treated macaques (Ctrl vs MPTP, 
mean ± SEM of nmol/mg protein; 0.16 ± 0.04 vs 0.36 ± 0.06, p = 0.0092; Fig. 1d), and such increase was normal-
ized by chronic L-DOPA administration (Ctrl vs MPTP + L-DOPA, mean ± SEM of nmol/mg protein; 0.16 ± 0.04 
vs 0.15 ± 0.02, p = 0.9115; MPTP vs MPTP + L-DOPA, 0.36 ± 0.06 vs 0.15 ± 0.02, p = 0.0075; Fig. 1d). MPTP 
also caused a significant variation in the striatal L-Asp content (F(2,12) = 3.887, p = 0.0500). Further statistical 
analysis revealed that MPTP alone was able to increase L-Asp levels (Ctrl vs MPTP, mean ± SEM of nmol/mg 
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proteins; 20.59 ± 3.60 vs 46.33 ± 10.45, p = 0.0282; Fig. 1e), which were normalized by L-DOPA treatment (Ctrl 
vs MPTP + L-DOPA, mean ± SEM of nmol/mg proteins; 20.59 ± 3.60 vs 22.34 ± 6.12, p = 0.8681; MPTP vs 
MPTP + L-DOPA, 46.07 ± 10.64 vs 22.34 ± 6.12, p = 0.0423; Fig. 1e). As a consequence of the concomitant varia-
tions in D- and L-Asp, we found that the ratio between D-Asp and total Asp (D- + L-Asp) was unchanged among 
the three groups analyzed (one-way ANOVA, F(2,12) = 0.49, p = 0.6236).
Interestingly, an increase, although not significant, was observed also in both D- and L-Ser levels in parkinso-
nian monkeys, which was again rescued by L-DOPA therapy (D-Ser: F(2, 12) = 2.67, p = 0.1101; L-Ser: F(2,12) = 3.05, 
p = 0.0849; Fig. 1f,g). These results are in line with those obtained in rat and mice, which showed a significant 
increase of striatal D-Ser levels as a consequence of bilateral DA denervation induced either by 6-OHDA or 
MPTP treatment, respectively25,27. The tendency to the transient increase of both D- and L-Ser in MPTP-treated 
monkeys was reflected in unchanged D-Ser/total Ser ratio among the three groups analyzed (one-way ANOVA, 
F(2,12) = 1.51, p = 0.2592). Overall, the ability of DA depletion and partial DA supplementation by L-DOPA to 
respectively increase and normalize the levels of D-Asp and D-Ser, and their relevant L-enantiomers, highlight 
the occurrence of a functional interaction between striato-nigral DA levels and amino acids homeostasis in the 
putamen of parkinsonian monkeys.
Finally, we measured the striatal content of L-Glu. Notably, HPLC measurements revealed no detectable dif-
ferences among the experimental groups (F(2,12) = 0.41, p = 0.6733; Fig. 1h).
Mptp treatment induces the selective reduction of the NMDAR co-agonist, D-serine, in the 
substantia nigra of parkinsonian monkeys. The changes in amino acids levels found in monkey putamen 
led us to evaluate their content also in a brain region functionally linked to the putamen and critically involved in 
PD, such as the SN. HPLC analysis showed no significant changes in D- and L-Asp levels in animals treated with 
MPTP or MPTP + L-DOPA, compared to controls (one-way ANOVA: D-Asp: F(2,12) = 1.47, p = 0.2688; L-Asp: 
F(2,12) = 2.41, p = 0.1315; Fig. 2a,b), as well as in L-Glu levels among the different experimental groups analyzed 
(F(2,12) = 1.61, p = 0.2407; Fig. 2e). Conversely, statistical analysis indicated that MPTP significantly affected 
D-Ser levels (F(2,12) = 3.91, p = 0.0493; Fig. 2c). In particular, we observed a decrease in D-Ser content (~30%) in 
monkeys treated with MPTP alone and with MPTP + L-DOPA, compared to untreated animals (Ctrl vs MPTP, 
mean ± SEM of nmol/mg proteins; 0.96 ± 0.07 vs 0.69 ± 0.05, p = 0.0268; Ctrl vs MPTP + L-DOPA, 0.96 ± 0.07 
vs 0.72 ± 0.10, p = 0.0398; Fisher’s post-hoc comparisons; Fig. 2c). On the other hand, no significant changes in 
the levels of L-Ser were detected in MPTP-treated macaques, with or without L-DOPA therapy (F(2,12) = 0.96, 
p = 0.4096; Fig. 2d). The analysis of D-Ser/total Ser ratio revealed significant changes among control, MPTP- and 
Figure 1. Effect of MPTP-induced striatal dopamine depletion and L-DOPA supplementation on free amino 
acids levels in the monkey putamen. (a) TH protein expression was detected by Western blotting in untreated 
(control), MPTP- and (MPTP + L-DOPA)-treated monkeys (n = 5 monkeys/treatment). TH variations are 
expressed as percentage of the control group. Representative blot of TH immunodensity comparing the 
experimental groups are shown above the graph. GAPDH was used to normalize for variations in loading 
and transfer. (b) Dopamine and (c) DOPAC (expressed as pg/mg of fresh tissue), and free amino acids (d) 
D-aspartate, (e) L-aspartate (f) D-serine, (g) L-serine and (h) L-glutamate (expressed as nmol/mg protein) were 
measured by HPLC in the same samples used for TH detection. All free amino acids were detected in a single 
run. **p < 0.01, ***p < 0.0001, compared to control group; #p < 0.05, ##p < 0.01, compared to MPTP-treated 
group (Fisher’s post-hoc). Dots represent the single subjects’ values while bars illustrate the means ± SEM.
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MPTP + L-DOPA-treated monkeys (one-way ANOVA: F(2,12) = 5.12, p = 0.0247). In particular, in line with D-Ser 
variation, this ratio was significantly reduced in MPTP-treated monkeys, compared to control animals (Ctrl vs 
MPTP, mean ± SEM of %; 16.83 ± 0.95 vs 12.33 ± 1.40, p = 0.0082). On the other hand, as a consequence of a 
slight L-Ser decrease in MPTP + L-DOPA-treated monkeys, D-Ser/total Ser ratio in these animals was compara-
ble to that found in control or MPTP-treated monkeys (Ctrl vs MPTP + L-DOPA, mean ± SEM of %, 16.8 ± 0.95 
vs 15.22 ± 0.50, p = 0.2788; MPTP vs MPTP + L-DOPA, 12.33 ± 1.40 vs 15.22 ± 0.50; p = 0.0657).
Altogether, these results highlight that in the SN of monkeys, MPTP treatment is able to trigger the selective 
reduction of D-Ser, thus suggesting an involvement of this NMDAR co-agonist in the neurochemical modifica-
tions of glutamatergic system associated to PD pathophysiology.
Unaltered D-aspartate and D-serine content in the medial frontal gyrus of Mptp-treated 
monkeys. We then addressed DA, DOPAC and amino acids detection in a region of the prefrontal cortex 
like the MFG. HPLC analysis indicated that MPTP treatment alone did not affect DA levels (one-way ANOVA: 
F(2,12) = 7.73, p = 0.0070; Ctrl vs MPTP, mean ± SEM of pg/mg tissue; 4.70 ± 0.52 vs 3.30 ± 0.53, p = 0.7254; 
Fisher’s post-hoc comparison; Fig. 3a), while chronic L-DOPA administration induced an increase of DA in 
MPTP-treated animals, compared to vehicle and MPTP alone administration (Ctrl vs MPTP + L-DOPA, 
mean ± SEM of pg/mg tissue; 4.70 ± 0.51 vs 17.20 ± 4.71, p = 0.0075; MPTP vs MPTP + L-DOPA, 3.30 ± 0.52 vs 
17.20 ± 4.71, p = 0.0039; Fig. 3a).
Figure 2. Effect of MPTP-induced striatal dopamine depletion and L-DOPA supplementation on free amino 
acids levels in the monkey substantia nigra. Free amino acids (a) D-aspartate, (b) L-aspartate (c) D-serine, (d) 
L-serine and (e) L-glutamate (expressed as nmol/mg protein) were measured by HPLC in untreated (control), 
MPTP- and (MPTP + L-DOPA)-treated monkeys (n = 5 monkeys/treatment). All free amino acids were 
detected in a single run. *p < 0.01, compared to control group (Fisher’s post-hoc). Dots represent the single 
subjects’ values while bars illustrate the means ± SEM.
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Then, we measured the levels of D- and L-amino acids. One-way ANOVA showed no main effect of MPTP 
treatment on D- and L-Asp amount (D-Asp: F(2,12) = 1.32, p = 0.3044; L-Asp: F(2,12) = 0.94, p = 0.4178; Fig. 3b,c). 
Likewise, D-Ser and L-Ser content was comparable among the different experimental groups (D-Ser: F(2,12) = 1.84, 
p = 0.2014; L-Ser: F(2,12) = 1.91, p = 0.1905; Fig. 3d,e). Interestingly, our results are consistent with unaltered D-Ser 
levels observed in the post-mortem cortex of PD brain36 and in the cortex of MPTP-lesioned mice27. Similarly to 
Asp and Ser enantiomers, no significant difference in L-Glu content among the different experimental groups 
analyzed were observed (F(2,12) = 1.47, p = 0.2674; Fig. 3f).
Overall, unaltered amino acids levels in the MFG suggest that MPTP is unable to affect their metabolism in a 
brain region functionally unrelated to basal ganglia circuit37, even under L-DOPA-dependent DA increase.
Mptp treatment induces an increase in D-amino acid oxidase mRNA and protein levels in the 
substantia nigra of monkeys. In order to gain insights into the molecular mechanisms responsible for the 
D-amino acids variations observed in the putamen and SN of MPTP-treated monkeys, we analyzed the expres-
sion of the genes regulating D-Asp (DDO) and D-Ser (DAAO and SR) metabolism. To this aim, we performed 
quantitative Real-Time PCR (qRT-PCR) analysis in the same brain samples used for HPLC detection. We found 
no alterations in DDO transcript levels within the putamen (one-way ANOVA, F(2,12) = 0.04, p = 0.9563; Fig. 4a), 
SN (F(2,12) = 2.66, p = 0.1105; Fig. 4d) and MFG (F(2,12) = 0.06, p = 0.9413; Fig. 4g) of parkinsonian monkeys with 
or without L-DOPA treatment, compared to naïve controls.
We then analysed the expression of the genes regulating D-Ser metabolism. Quantitative RT-PCR revealed 
that DAAO mRNA was undetectable (up to 40 cycles) in the striatal and cortical samples tested (Fig. 4b,h). 
Conversely, in line with previous evidence in humans38, DAAO transcript was expressed in the SN (at ∼30 cycles; 
Fig. 4e) where it is significantly affected by MPTP treatment (F(2,12) = 4.39, p = 0.0370; Fig. 4e). In particular, 
regardless of L-DOPA administration, we observed a significant increase in DAAO mRNA levels in parkinso-
nian monkeys, compared to naïve controls (Ctrl vs MPTP: p = 0.0285; Ctrl vs MPTP + L-DOPA: p = 0.0216, 
Fisher’s post-hoc comparisons; Fig. 4e). On the other hand, qRT-PCR data revealed no differences in SR mRNA 
expression among the experimental groups in each brain region analyzed (putamen: F(2,12) = 1.55, p = 0.2526; SN: 
F(2,12) = 0.52, p = 0.6092; MFG: F(2,12) = 0.97, p = 0.4060; Fig. 4c,f,i).
Figure 3. Effect of MPTP-induced striatal dopamine depletion and L-DOPA supplementation on free amino 
acids levels in the monkey medial frontal gyrus. (a) Dopamine (expressed as pg/mg of fresh tissue), and free 
amino acids (b) D-aspartate, (c) L-aspartate (d) D-serine, (e) L-serine and (f) L-glutamate (expressed as nmol/
mg protein) were measured by HPLC in untreated (control), MPTP- and (MPTP + L-DOPA)-treated monkeys 
(n = 5 monkeys/treatment). All free amino acids were detected in a single run. **p < 0.01, compared to control 
group; ##p < 0.01, compared to MPTP-treated group (Fisher’s post-hoc). Dots represent the single subjects’ 
values while bars illustrate the means ± SEM.
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Figure 4. mRNA and protein expression of DDO, DAAO and SR in the brain of parkinsonian monkeys. 
(a,d,g) DDO, (b,e,h) DAAO and (c,f,i) SR mRNA expression was detected by quantitative RT-PCR in the 
(a–c) putamen, (d–f) substantia nigra and (g-i) medial frontal gyrus of untreated (control), MPTP- and 
(MPTP + L-DOPA)-treated monkeys (n = 5 monkeys/treatment). mRNA expression is normalized to the 
mean of three housekeeping genes and expressed as arbitrary units. (b,h) N.D. indicates that DAAO transcript 
was not detectable up to 40 cycles. (j) DAAO and (k) SR protein levels were detected by Western blotting in 
the same putamen and substantia nigra samples used for quantitative RT-PCR. (j) N.D. indicates that DAAO 
protein was not detectable. Proteins variations are expressed as percentage of the control group. Representative 
blots of DAAO and SR immunodensity comparing the experimental groups are shown above the graph. Full-
length blots are presented in Supplementary Fig. S1. Tubulin was used to normalize for variations in loading 
and transfer. *p < 0.05, compared to control group (Fisher’s post-hoc). Dots represent the single subjects’ values 
while bars illustrate the means ± SEM.
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In order to understand whether gene transcription results are reflected also at translational level and whether 
changes in D-amino acids content could be functionally explained by variations in protein expression, we inves-
tigated DAAO and SR protein content in the brain of MPTP-treated macaques, compared to naïve animals. In 
line with mRNA detection, Western blot analysis indicated that DAAO protein was undetectable in the putamen 
samples (Fig. 4j). Conversely, we found a significant main effect of MPTP on DAAO protein levels in the SN 
(F(2,9) = 4.28, p = 0.0495; Fig. 4j). In particular, in line with qRT-PCR analysis, MPTP treatment was associated to 
a significant increase in DAAO protein in parkinsonian monkeys (Ctrl vs MPTP: p = 0.0230; Fig. 4j). However, 
chronic L-DOPA supplementation was able to normalize the expression of this enzyme (Ctrl vs MPTP + L-DOPA: 
p = 0.4396; Fig. 4j). Finally, no significant changes in SR levels in both putamen and SN samples were detected 
among different experimental groups (putamen: F(2,12) = 0.76, p = 0.4884; SN: F(2,12) = 0.60, p = 0.5608; Fig. 4k).
Analysis of glutamatergic NMDA, AMpA, mGLU receptors levels in the putamen and substan-
tia nigra of MPTP-treated parkinsonian monkeys. Based on dysfunctional glutamatergic transmission 
observed in preclinical models and PD patients13, we measured the total protein amounts of the main NMDA and 
AMPA receptor subunits, and of the metabotropic glutamate receptors, mGluR2/3 and mGluR5, in the putamen 
and SN of MPTP-treated macaques with and without L-DOPA treatment, compared to naïve animals.
Western blot analysis indicated no main differences in the striatal expression of the NMDAR subunits GluN1, 
GluN2A and GluN2B between parkinsonian monkeys and controls (one-way ANOVA, GluN1: F(2,12) = 1.67, 
p = 0.2294; GluN2A: F(2,12) = 1.53, p = 0.2549; GluN2B: F(2,12) = 0.81, p = 0.4685; Fig. 5a-c). Similarly, MPTP 
treatment did not perturb the expression of the AMPAR subunits GluA1 and GluA2/3 (GluA1: F(2,12) = 2.10, 
p = 0.1689; GluA2/3: F(2,12) = 0.21, p = 0.8106; Fig. 5d,e), and metabotropic glutamate receptors mGluR2/3 and 
mGluR5 (mGluR2/3: F(2,12) = 0.04, p = 0.9613; mGluR5: F(2,12) = 0.08, p = 0.9202; Fig. 5f,g). In agreement with our 
results, previous reports did not observe significant changes in striatal glutamate receptor levels in the non-human 
primate model both by binding studies39,40 and by evaluation of total protein levels through Western blotting10,41. 
Unlike, fractioning experiments showed altered expression of AMPA and NMDAR subunits in MPTP-treated 
macaques10,42, thus suggesting that altered synaptic localization of specific glutamate receptor subtypes and con-
sequent functional alteration, rather than an aberrant total expression level, represent the main event at striatal 
excitatory synapses in PD4,7,8.
Differently from the putamen, MPTP treatment induced a L-DOPA-insensitive trend to reduction of the 
fundamental GluN1 subunit in the SN of parkinsonian monkeys (F(2,12) = 3.13, p = 0.0802; Fig. 5h). Conversely, 
the levels of GluN2A subunit appeared comparable among the different experimental groups (F(2,12) = 0.53, 
p = 0.6032; Fig. 5i). Similarly to GluN1, also the GluN2B expression was reduced in the SN of parkinsonian mon-
keys, although such decrease failed to reach the statistical significance (F(2,12) = 1.30, p = 0.3083; Fig. 5j). Western 
blot analysis also indicated unaltered levels of the AMPAR subunits, GluA1 and GluA2/3 (GluA1: F(2,12) = 0.57, 
p = 0.5787; GluA2/3: F(2,12) = 0.16, p = 0.8517; Fig. 5k,l). Furthermore, consistently with previous studies43, we 
confirmed that mGluR2/3 protein was undetectable in the SN samples (Fig. 5m), while a trend to decrease of 
mGluR5 levels in MPTP-treated animals was observed, compared to controls (F(2,9) = 2.39, p = 0.1473; Fig. 5n).
D-serine concentration is reduced in the cerebrospinal fluid of L-DOPA-free Parkinson’s disease 
patients. To translate our preclinical observations to humans, we measured the serum content of Asp and Ser 
enantiomers, and L-Glu in PD patients and control subjects. HPLC analysis revealed unchanged D-Asp content 
in L-DOPA-free and L-DOPA-treated PD patients, compared to control subjects (Kruskal-Wallis test, p = 0.9370; 
Fig. 6a). Similarly, we revealed no significant L-Asp alterations among experimental groups (p = 0.3935; Fig. 6b). 
We also found comparable amount of D-Ser and L-Ser in the serum of both L-DOPA-free and L-DOPA-treated 
PD patients, compared to control subjects (D-Ser: p = 0.5233; L-Ser: p = 0.8616; Fig. 6c,d). Likewise, serum L-Glu 
content was unaltered among the three groups analyzed (p = 0.1221; Fig. 6e).
We extended HPLC analysis to the CSF of the same patients. Notably, we found that D-Asp content was 
below our HPLC detection limit (<0.01 pmol; Fig. 6f) in all samples analyzed, while the L-Asp content was 
unaltered in L-DOPA-free and L-DOPA-treated PD patients, compared to control subjects (Kruskal-Wallis 
test, p = 0.9475; Fig. 6g). On the other hand, statistical analysis revealed a significant variation of D-Ser levels 
among the three groups analyzed (p = 0.0043; Fig. 6h). In this regard, the following post-hoc comparison showed 
a significant decrease (~35%) of D-Ser content in the CSF of PD patients without L-DOPA treatment, com-
pared to controls (Ctrl vs L-DOPA-free, mean ± SEM of µM, 4.96 ± 0.22 vs 3.20 ± 0.46, Dunn’s test, p = 0.0010; 
Fig. 6h). Interestingly, such decrease was not found in PD patients treated with L-DOPA (Ctrl vs L-DOPA, 
mean ± SEM of µM, 4.96 ± 0.22 vs 4.52 ± 0.36; p = 0.2616; L-DOPA-free vs L-DOPA, 3.20 ± 0.46 vs 4.52 ± 0.36; 
p = 0.0497; Fig. 6h). Unlike D-Ser, we did not reveal significant alterations in L-Ser content in the CSF of PD 
subjects, regardless of L-DOPA treatment, compared to control subjects (p = 0.1068; Fig. 6i). The variations in 
D-Ser content among the three groups analyzed were also confirmed by the analysis of D-Ser/total Ser ratio 
(Ctrl vs L-DOPA-free, mean ± SEM of %, 8.57 ± 0.32 vs 7.01 ± 0.30; p = 0.0117; Ctrl vs L-DOPA, 8.57 ± 0.32 vs 
8.15 ± 0.52; p = 0.5458; L-DOPA-free vs L-DOPA, 7.01 ± 0.30 vs 8.15 ± 0.52; p = 0.0884).
Finally, we observed comparable L-Glu content in control, L-DOPA-free and L-DOPA-treated PD patients 
(p = 0.8611; Fig. 6j).
Discussion
Nowadays, structural, functional and synaptic modifications occurring at NMDARs in PD represent a topic of 
intense investigation since these receptors are postulated to play a primary role in the progression and treatment 
of this neurodegenerative disease13,44–46. Here, we explored the consequences of dopaminergic denervation on the 
metabolism of the NMDAR modulators, D-Asp and D-Ser, in the brain of MPTP-lesioned macaques, and in the 
serum and CSF of PD patients, with or without L-DOPA therapy.
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We report for the first time that the gold-standard PD primate model shows a significant D-Ser reduction 
in the SN. In line with our observation in primates, a reduction of D-Ser content was also reported in the mid-
brain of MPTP-treated mice26. These results suggest that the decreased availability of the NMDAR co-agonist 
D-Ser may represent a common compensatory mechanism to counteract NMDAR-mediated toxicity and, ulti-
mately, dopaminergic neuronal death in the SN of MPTP models of PD. Moreover, we also found a trend of 
reduction in the protein expression of the NMDAR subunits, GluN1 and GluN2B, and mGlu5 receptors, thus 
Figure 5. Expression levels of glutamatergic receptors in the brain of parkinsonian monkeys. Protein 
expression levels of the (a–c, h–j) NMDARs subunits (a,h) GluN1, (b,i) GluN2A, (c,j) GluN2B, (d–e, k–l) 
AMPAR subunits (d,k) GluA1 and (e,l) GluA2/3, and (f,g, m,n) metabotropic glutamate receptors (f,m) 
mGluR2/3 and (g,n) mGluR5 were detected in the (a–g) putamen and (h–n) substantia nigra of untreated 
(control), MPTP- and (MPTP + L-DOPA)-treated monkeys (n = 5 monkeys/treatment)by Western blotting. 
(m) N.D. indicates that protein levels were not detectable. Proteins variations are expressed as percentage of the 
control group. Representative blots of each subunit or receptor immunodensity comparing the experimental 
groups are shown above the graph. Tubulin was used to normalize for variations in loading and transfer. Dots 
represent the single subjects’ values while bars illustrate the means ± SEM.
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disclosing the possible existence of an overall hypo-glutamatergic transmission in the SN of parkinsonian mon-
keys. Interestingly, the neurochemical observations obtained in the SN of MPTP-lesioned monkeys also provide 
a possible rationale to explain the beneficial effect of D-Ser add-on administration on motor and non-motor 
symptoms of PD patients28. Indeed, D-Ser administration may aid in restoring the endogenous levels of this 
D-amino acid and, in turn, the balance between NMDAR-related pro-death and pro-survival signaling path-
ways in the residual midbrain neurons, as hypothesized by Heresco-Levy and coworkers47. Yet, amelioration 
of the defective NMDAR signaling at glycine-binding site in the spared midbrain dopaminergic neurons may 
enhance nigro-striatal DA release and synaptic transmission48,49, thus improving the clinical responses of PD 
patients. On the other hand, based on the “double-edged sword” of NMDAR stimulation50,51, we cannot exclude 
that long-lasting D-Ser adjuvant treatment in PD patients might determine detrimental effects by increasing the 
progression-rate of midbrain TH-positive neurons degeneration. Therefore, future investigations are mandatory 
to confirm D-Ser safety at high doses and, most importantly, for longer treatment periods in large cohorts of PD 
patients, as previously reported in schizophrenia-diagnosed subjects52. Alternatively, to avoid the potential toxic-
ity of D-Ser administration, another possible route might be pursued in PD therapeutics through the inhibition 
of DAAO by sodium benzoate, which has been already successfully applied in the treatment of schizophrenia and 
Alzheimer’s disease53.
Besides D-Ser decrease in the SN, we observed that MPTP treatment induces a robust augmentation of D-Asp 
and L-Asp levels in the primate putamen, coupled to a trend increase of D-Ser and L-Ser. Interestingly, the partial 
restoration of DA levels by L-DOPA was sufficient to rescue the levels of both Asp and Ser enantiomers. Based on 
the knowledge that NMDAR stimulation enhanced DA synthesis and release within the striatum48, and consid-
ering the common ability of L-Asp, D-Asp and D-Ser to directly stimulate NMDARs54–56, and the role of L-Ser 
as precursor of D-Ser biosynthesis21, we speculate that the variations in these amino acids content under DA 
denervation represent an attempt of striatal circuitry to counteract the reduction of nigro-striatal dopaminergic 
transmission. In support of a dynamic interaction between DA levels and neuroactive amino acids, Moratalla and 
co-workers reported an overall increase in glutamine, glycine and taurine levels in the striatum of unilaterally 
lesioned 6-OHDA mice, which was normalized by L-DOPA supplementation57.
Despite the L-DOPA-sensitive D-Asp alterations reported in the putamen of MPTP-treated monkeys, we 
found no significant change in DDO mRNA expression among the experimental groups. Considering that in the 
putamen of parkinsonian monkeys both Asp enantiomers were significantly up-regulated, as indicated by the 
lack of significant difference in the D-Asp/total Asp ratio, we cannot rule out that changes in D-Asp levels may be 
a secondary effect of L-Asp accumulation and, therefore, independent by direct changes in D-Asp degradation. 
Figure 6. Free amino acids levels in the serum and cerebrospinal fluid of patients with Parkinson’s disease. Free 
amino acids (a,f) D-aspartate, (b,g) L-aspartate (c,h) D-serine, (d,i) L-serine and (e,j) L-glutamate (expressed 
as μM) were measured by HPLC (a-e) in the serum of control subjects (n = 27 for D-aspartate; n = 29 for 
other amino acids), L-DOPA-free (n = 8) and L-DOPA-treated (n = 12 for D-aspartate; n = 13 for other amino 
acids) PD patients, and (f–j) in the cerebrospinal fluid of control subjects (n = 28 for L-aspartate; n = 30 for 
other amino acids), L-DOPA-free (n = 9) and L-DOPA-treated (n = 12) PD patients. (f) N.D. indicates that 
D-aspartate levels were not detectable since they were below the detection limit (<0.01 pmol). In each tissue, 
all free amino acids were detected in a single run. **p < 0.01, compared to control group; #p < 0.05, compared 
to L-DOPA-free PD patients (Dunn’s test). Dots represent the single subjects’ values while bars illustrate the 
means ± SEM.
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However, the lack of available selective anti-DDO antibodies prevented to assess whether changes in striatal 
D-Asp content may also depend on alterations of DDO protein levels. Conversely, the pathway responsible for 
D-Asp biosynthesis in mammals is still unknown and, therefore, we cannot evaluate potential changes in the 
de novo synthesis of this D-amino acid in parkinsonian monkeys. Nonetheless, recent findings revealed that 
SR might partially generate D-Asp, in addition to D-Ser58,59. However, as discussed below for D-Ser, our results 
exclude any alteration in both SR mRNA and protein levels in MPTP-treated monkeys.
Regarding the metabolic regulation of D-Ser, we did not find any change in SR transcript levels between 
MPTP-lesioned monkeys, with or without L-DOPA administration, and control group, in each brain region ana-
lyzed. Differently to what observed by Lu and co-workers in MPTP-treated mice27, our experiments indicated 
also a comparable amount of SR protein among treatment groups in the different brain regions tested, thus sug-
gesting the existence of species-specific SR regulation under PD conditions. On the other hand, we highlighted a 
significantly increased DAAO mRNA expression in the SN of both MPTP and MPTP + L-DOPA groups, coupled 
to increased DAAO protein levels selectively in MPTP-treated monkeys, thus supporting the reduction in D-Ser 
found in the SN of these animals. Future studies are required to find out whether the upregulation of DAAO takes 
place in astrocytes and/or in dopaminergic midbrain neurons, where the expression of this gene has been previ-
ously detected60,61. Interestingly, despite increased DAAO mRNA levels, we found that L-DOPA supplementation 
normalized DAAO protein expression in PD monkeys. Therefore, while our data suggest that the lower content of 
D-Ser in the SN of MPTP-lesioned monkeys originates from the over-expression of DAAO gene, it remains still 
unclear whether other mechanisms contribute to down-regulate D-Ser levels in L-DOPA-treated PD monkeys. 
Future studies are warranted to clarify this issue, although we excluded a direct effect of L-DOPA and DA on 
human DAAO and SR activity in in vitro assays (see Supplementary Results and Supplementary Tables).
In addition to D-Ser decrease in the SN of MPTP-lesioned monkeys, in the present work we unveiled a sig-
nificant D-Ser reduction also in the CSF of L-DOPA-free PD patients. This result suggests that profound changes 
in NMDAR-mediated neurotransmission occur in PD patients, as well as in animal models of PD, and these 
alterations involve the modulation of the co-agonist D-Ser, rather than the main agonist L-Glu. Of note, L-DOPA 
therapy in patients is able to normalize D-Ser content at control levels, further indicating the existence of a func-
tional interaction between DA and D-Ser. However, future studies are mandatory to identify the specific cerebral 
regions responsible for D-Ser alterations found in the CSF of L-DOPA-free PD patients. This issue gains more 
importance if we consider that in parkinsonian monkeys, DA depletion and its replacement with L-DOPA affect 
D-Ser levels in a region-specific manner. Unlike CSF, we found that the serum levels of D-Ser are comparable 
among the different groups analyzed, implying that the metabolic alteration of this NMDAR co-agonist in PD is 
selective for the central nervous system, rather than being a more generalized event involving peripheral organs.
Experimental limitations should be taken into account for the interpretation of our data. First, the low number 
of monkey brain and human serum/CSF samples could affect the robustness of our observations. Second, the sub-
jects used as control group (other neurological disorders) suffer from heterogeneous clinical diseases including 
headache, epilepsy, psychiatric disorders, and white matter lesions (see Table 1) that may underlie dysfunctions 
in glutamatergic system. Therefore, we cannot exclude that this potential bias may have masked further amino 
acids deregulations occurring in the serum and/or CSF of PD patients, thus impacting as confounding factor on 
our neurochemical analyses. Third, in regard to SN samples, we could not discriminate between pars compacta 
and pars reticulata. Thus, the MPTP-dependent changes in D-Ser concentration observed in the SN could rep-
resent an underestimation of what we might have found in the pars compacta alone, which is the area selectively 
involved in PD-related cell death. Fourth, the analysis of the whole monkey brain homogenates does not allow us 
to understand whether changes in D-amino acids levels are due to loss of DA cell bodies or originate from expres-
sion changes in other neuronal or glial sources in response to DA neurons loss. Moreover, we cannot dissociate 
between total content and extracellular active fraction of amino acids. Therefore, while the observations in the 
CSF most likely reflect the neurochemical content of the extracellular milieu, further in vivo microdialysis studies 
are necessary in PD monkey brain to understand whether the variations observed in homogenates mirror those 
occurring at extracellular level.
In conclusion, the present study highlights in both non-human primates and humans an involvement of 
D-amino acids in the pathophysiology of PD and its pharmacological treatment. In particular, we hypothesize 
that D-Ser and D-Asp variations in the SN and putamen of parkinsonian monkeys might represent adaptive 
neuronal mechanisms to limit NMDAR-mediated midbrain neurotoxicity and counteract the reduction of 
nigro-striatal dopaminergic transmission13,62–65. On the other hand, changes in the SN of primates provide the 
first possible explanation for the clinical benefit of D-Ser add-on administration observed in patients with severe 
PD28,47.
Methods
Non-human primates. Captive bred female macaques (Macaca mulatta, Xierxin, Beijing, PR of China; 
mean age = 5 ± 1 years; mean weight = 5.3 ± 0.8 kg), were housed in individual primate cages under controlled 
conditions of humidity (50 ± 5%), temperature (24 ± 1 °C), and light (12 h light/12 h dark cycles, time lights on 
8:00 am), and allowing visual contacts and interaction with macaques housed in the adjacent cages. Food and 
water were available ad libitum and animal care was supervised daily by veterinarians skilled in the healthcare and 
maintenance of non-human primates. Experiments were carried out in accordance with European Communities 
Council Directive (2010/63/EU) for care of laboratory animals in an AAALAC-accredited facility following 
acceptance of study design by the Institute of Lab Animal Science IACUC (Chinese Academy of Medical Sciences, 
Beijing, China). The tissues used in the present work have been obtained from an experimental brain bank used 
in several occasions whose experimental conditions are described elsewhere in great details. MPTP-treated 
non-human primate PD model macaques (n = 10) received daily MPTP hydrochloride injections (0.2 mg/kg, 
intravenously) until parkinsonian signs appeared34,66–73. Once PD motor signs were stable, some of the animals 
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(n = 5) were treated twice daily with an individually titrated dose of L-DOPA that provided maximum reversal of 
parkinsonian motor signs (Madopar, L-DOPA/carbidopa, 4:1 ratio; range, 9–17 mg/kg). This dose of L-DOPA, 
defined as 100% dose, was used for chronic L-DOPA treatment, which lasted for 4 to 5 months until dyskinesia 
stabilized. Animals then received L-DOPA twice a week to maintain a consistent level of dyskinesia before acute 
drug tests were carried out using a within subject experimental design. At the end of the experiment, all animals 
were killed by sodium pentobarbital overdose (150 mg/kg, i.v.) 1 h after the last dose of vehicle or L-DOPA (i.e. at 
peak of antiparkinsonian effect), and the brains were removed quickly after death. Each brain was bisected along 
the midline and the two hemispheres were immediately frozen by immersion in isopentane (−45 °C) and then 
stored at −80 °C. Coronal 300 μm-thick sections were cryostat-cut and punches of brain tissue were taken for the 
following regions: motor striatum (post-commissural dorsal putamen), prefrontal cortex (MFG), and substantia 
nigra. An average sample size of 6 ± 2 mg was obtained34,71.
Human serum and cerebrospinal fluid collection. Serum and cerebrospinal fluid samples were 
obtained from the Center for Memory Disturbances, University Hospital of Perugia (Italy). The patients (n = 22 
of which 9 were L-DOPA-free and 13 were treated with L-DOPA) were diagnosed with PD according to United 
Kingdom Brain Bank Society (UKBBS) criteria74,75. As neurological controls (n = 30), subjects who under-
went lumbar puncture or blood sampling for diagnostic reasons but without clinical evidence of dementia 
were enrolled. The commonest control diagnoses were headache, epilepsy, psychiatric disorders, and white 
Control Parkinson’s disease
ID Sex Age (years) Diagnosis ID Sex Age (years) Diagnosis
L-DOPA 
therapy
1 F 73 Behavior disorders 1 M 64 PD No
2 M 46 Headache 2 M 63 PD No
3 M 63 Epilepsy with cognitive deficits 3 F 43 PD No
4 F 56 Behavior disorders 4 M ? PD No
5 F 74 Epilepsy 5 M 64 PD No
6 F 71 Polyfactorial 6 M 73 PD No
7 F 53 White matter injury 7 M 69 PD No
8 M 67 Polyfactorial 8 F 60 PD No
9 F 64 Subjective memory impairment 9 F 66 PD No
10 F 68 Control 10 M 86 PD Yes
11 M 48 Subjective memory impairment 11 M 61 PD Yes
12 M 72 Metabolic encephalopathy 12 M 43 PD Yes
13 F 60 Transient global amnesia 13 M 70 PD Yes
14 F 69 Psychiatric 14 F 74 PD Yes
15 M 68 Epilepsy 15 M 81 PD Yes
16 M 78 Wernicke’s encephalopathy 16 F 59 PD Yes
17 F 51 Vascular encephalopathy 17 M 74 PD Yes
18 M 76 Cognitive deficits 18 F 61 PD Yes
19 M 67 Senile psychosis 19 F 76 PD Yes
20 F 82 Late-onset epilepsy with cognitive deficits 20 M 75 PD Yes
21 F 49 Epilepsy 21 M 64 PD Yes
22 M 72 Dysmetabolic polyneuropathy with cognitive deficits 22 M 63 PD Yes
23 F 77 Other neurological disorder
24 M 81 III cranial nerve
25 M 71 Psychiatric with cognitive deficits
26 F 71 Transient global amnesia
27 M 64 Transient global amnesia
28 F 76 Epilepsy
29 M 65 Psychiatric
30 F 64 Late-onset epilepsy
Total Total Mean ± SEM Total Total Mean ± SEM
30 M = 14/F = 16 66.5 ± 1.8 22 M = 15/F = 7 66.1 ± 2.3
Table 1. Demographic and clinical characteristics of Parkinson’s disease and control subjects. Abbreviations: 
F = female, M = male, PD = Parkinson’s Disease.
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matter lesions. The exclusion criteria for the control group were dementia disorders, atypical parkinsonism (i.e., 
multiple system atrophy, corticobasal syndrome, progressive supranuclear palsy), and systemic and neoplastic 
diseases. Groups did not differ significantly for age (Ctrl vs L-DOPA-free vs L-DOPA-treated, mean ± SEM of 
years: 66.5 ± 1.8 vs 62.7 ± 3.1 vs 68.2 ± 3.1, p = 0.3995, Kruskal-Wallis test) and gender (χ2 = 2.396, p = 0.3018, 
χ2 test). Further details are reported in Table 1. All subjects included in the study gave their informed written 
consent to undergo lumbar puncture and to allow us to use the biological samples also for scientific purposes 
(the sheets of informed written consent report several items explaining thoroughly each issue regarding the 
meaning and aims of the lumbar puncture and following analysis: what is lumbar puncture; why it is carried 
out; measurements carried out in biological samples; possible scientific use of them, including their sharing with 
other centers for scientific purposes). This procedure is routinely done since 2008, according to the Local Ethical 
Committee approval, CEAS (Comitato Etico Aziende Sanitarie Umbria) (Prot. N. 19369/08/AV, Oct 09 2008). 
CSF collection was performed according to international guidelines76. Briefly, lumbar puncture was performed 
between 8:00 AM and 10:00 AM, after an overnight fast. CSF (10 mL) was taken from the L3-L4 or L4-L5 inter-
space, immediately collected into sterile polypropylene tubes (Sarstedt, Code 62.610.201) and gently mixed to 
avoid possible gradient effects. Within 1 h from collection, CSF sample was centrifuged at 2000 × g for 10 min 
at room temperature, divided into 0.5 mL aliquots in polypropylene cryotubes (Sarstedt, code 72.730007) and 
stored at –80 °C. Whole blood was collected by peripheral venipuncture into clot activator tubes (Kima, code 
11020) and gently mixed. Sample was stored upright for 30 min at room temperature to allow blood to clot, 
and centrifuged at 2000 × g for 10 min at room temperature. Serum was aliquoted (0.5 ml) in polypropylene 
cryotubes and stored at –80 °C.
Neurochemical DA and DOPAC detection in monkey brains. Dopamine and its metabolite DOPAC 
tissue content was analyzed as previously described77. Samples were weighted and homogenized by sonica-
tion in 0.1 N HClO4 (1:20, w/v), centrifuged at 10,000xg, the supernatant filtered on micro-centrifuge filters 
(0.22 µm nylon filter, Costar Spin-X, Corning, NY, USA) and directly injected into the HPLC. The HPLC sys-
tem was equipped with a Symmetry column (3.0 × 150 mm, C18, 3.5 µm, Waters, Milan, Italy), kept at 38 °C by 
a Series 1100 thermostat (Agilent Technologies, Waldbronn, Germany). The detector was an ESA Coulochem 
II (Chelmford, MA, USA), whose analytical cell was set with the first electrode at +200 mV, the second one at 
−300 mV. Only the second electrode signal was recorded and analyzed. The mobile phase consisted in 80 mM 
Na2HPO4, 0.27 mM EDTA, 0.6 mM sodium octyl sulfate, 8% methanol, 4% acetonitrile, pH 2.8 with H3PO4, deliv-
ered at 0.30 ml/min. In these conditions, the detection limit (signal to noise ratio 3:1) was 0.3 pg of DA on column. 
Data are expressed as pg/mg tissue. Statistical analyses were performed by one-way ANOVA, followed by Fisher’s 
post-hoc comparison, when required.
Neurochemical analysis of amino acids content. Brain tissue samples of monkeys were homogenized 
in 1:20 (w/v) 0.2 M TCA, sonicated (3 cycles, 10 s each) and centrifuged at 13,000xg for 20 min. All the pre-
cipitated protein pellets from brain samples were stored at −80 °C for protein quantification. Human serum 
or CSF samples (100 µl) were mixed in a 1:10 dilution with HPLC-grade methanol (900 µl) and centrifuged at 
13,000xg for 10 min; supernatants were dried and then suspended in 0.2 M TCA. TCA supernatants from mon-
key and human samples were then neutralized with NaOH and subjected to pre-column derivatization with 
o-phthaldialdehyde/N-acetyl-L-cysteine. Diastereoisomer derivatives were resolved on a Simmetry C8 5-μm 
reversed-phase column (Waters, 4.6 × 250 mm). Identification and quantification were based on retention times 
and peak areas, compared with those associated with external standards. The identity of peaks was confirmed by 
selective enzymatic degradation30,78. Total protein content of homogenates was determined by Bradford assay 
method, after resolubilization of the TCA precipitated protein pellets. The detected amino acids concentration in 
tissue homogenates was normalized by the total protein content and expressed as nmol/mg protein; amino acids 
level in the serum and CSF was expressed as µM. Statistical analyses in monkey brain were performed by one-way 
ANOVA, followed by Fisher’s post-hoc comparison, when required. Human serum and CSF data were analyzed 
by Kruskal-Wallis test, followed by Dunn’s test, when required.
Quantitative Real Time PCR analysis. Total RNAs were extracted using RNeasy® Mini kit (Quiagen, Hilden, 
Germany), according to the manufacturer’s instructions. Total RNA was purified to eliminate potentially contami-
nating genomic DNA using recombinant DNAse. We used 0.2 μg of total RNA per sample to synthesize cDNA. After 
total RNA extraction (0.2 µg), qRT-PCR amplifications were performed with LightCycler 480 SYBR Green I Master 
(Roche Diagnostic), in a LightCycler 480 Real Time thermocycler (Roche). The following protocol was used: 10 s 
for initial denaturation at 95 °C followed by 40 cycles consisting of 10 s at 94 °C for denaturation, 10 s at 65 °C for 
annealing, and 6 s for elongation at 72 °C temperature. The following primers were used for DDO, DAAO and SR 
cDNA amplification: DDO fw: GCAGTGGTTCAGAGAGACCT and DDO rev: CGAAATCCCAGAACCACGTC; 
DAAO fw: GGAAGGACACAGTTCTGGGA and DAAO rev: CTTCTCTTGCCACCTCCTCA; SR fw: 
AACCAGGTTCCTTTGGTGGA and SR rev: CCCTTCAGCTTGGACTGGTA. Transcripts quantities were 
normalized by the geometric mean of the three housekeeping genes, Actin b (ACTB), GAPDH and Cyclophilin 
A (PPIA), which were amplified using the following primers: PPIA fw: TGCTGGACCCAACACAAATG 
and PPIA rev: GTCCACAGTCAGCAATGGTG; GAPDH fw: AGGTCGGAGTCAACGGATTT and 
GAPDH rev: ATCTCGCTCCTGGAAGATGG; ACTB fw: CTGTGCTATGTCGCCCTAGA and ACTB rev: 
GGAAGGTTGGAAGAGAGCCT. All measurements from each subject were performed in duplicate. mRNA 
expression was calculated using the relative quantification method (2−ΔΔCt). Statistical analyses were performed by 
one-way ANOVA, followed by Fisher’s post-hoc comparison, when required.
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Western blotting. Preparation and immunoblotting were performed as previously described78. Frozen, pow-
dered samples from post-mortem brains were sonicated in 1% SDS and boiled for 10 min. Proteins were separated 
by SDS-PAGE and electroblotted onto PVDF membranes (GE-Healthcare). Immunodetections were accom-
plished by using the following antibodies: anti-SR (1:500, Santa Cruz Biotechnology, Santa Cruz, CA, USA), 
anti-DAAO (1:1000, Everest Biotech Ltd, Oxfordshire, UK), anti-GluN1 (1:1000, Cell Signaling Technology, 
Beverly, MA, USA), anti-GluN2A (1:1000, Sigma, St. Louis, MO, USA), anti-GluN2B (1:1000, Cell Signaling 
Technology), anti-GluR1, anti-GluR2/3 (1:1000, Merck Millipore, Darmstadt, Germany), anti-mGluR2/3 (1:1000, 
Merck Millipore), anti-mGluR5 (1:1000, Abcam, Cambridge, UK), anti-α-tubulin (1:50000, Sigma), anti-tyrosine 
hydroxylase (1:2000, Merck Millipore), anti-GAPDH (1:1000, Santa Cruz Biotechnology). Blots were then incu-
bated in horseradish peroxidase-conjugated secondary antibodies. Immunoreactivity was detected by enhanced 
chemiluminescence (ECL) (GE-Healthcare) and quantified by Quantity One software (Bio-Rad). Optical density 
values were normalized to α-tubulin or GAPDH for variations in loading and transfer. Statistical analyses were 
performed by one-way ANOVA, followed by Fisher’s post-hoc comparison, when required.
References
 1. Obeso, I. et al. Unilateral subthalamotomy in Parkinson’s disease: Cognitive, psychiatric and neuroimaging changes. Cortex 94, 
39–48, https://doi.org/10.1016/j.cortex.2017.06.006 (2017).
 2. Poewe, W. et al. Parkinson disease. Nat Rev Dis Primers 3, 17013, https://doi.org/10.1038/nrdp.2017.13 (2017).
 3. LeWitt, P. A. Levodopa therapy for Parkinson’s disease: Pharmacokinetics and pharmacodynamics. Mov Disord 30, 64–72, https://
doi.org/10.1002/mds.26082 (2015).
 4. Bastide, M. F. et al. Pathophysiology of L-dopa-induced motor and non-motor complications in Parkinson’s disease. Prog Neurobiol 
132, 96–168, https://doi.org/10.1016/j.pneurobio.2015.07.002 (2015).
 5. DeLong, M. R. & Wichmann, T. Circuits and circuit disorders of the basal ganglia. Arch Neurol 64, 20–24, https://doi.org/10.1001/
archneur.64.1.20 (2007).
 6. Ahmed, I. et al. Glutamate NMDA receptor dysregulation in Parkinson’s disease with dyskinesias. Brain 134, 979–986, https://doi.
org/10.1093/brain/awr028 (2011).
 7. Gardoni, F. & Bellone, C. Modulation of the glutamatergic transmission by Dopamine: a focus on Parkinson, Huntington and 
Addiction diseases. Front Cell Neurosci 9, 25, https://doi.org/10.3389/fncel.2015.00025 (2015).
 8. Mellone, M. & Gardoni, F. Glutamatergic mechanisms in L-DOPA-induced dyskinesia and therapeutic implications. J Neural 
Transm (Vienna) 125, 1225–1236, https://doi.org/10.1007/s00702-018-1846-8 (2018).
 9. Calabresi, P., Giacomini, P., Centonze, D. & Bernardi, G. Levodopa-induced dyskinesia: a pathological form of striatal synaptic 
plasticity? Ann Neurol 47, S60–68; discussion S68–69 (2000).
 10. Hallett, P. J. et al. Alterations of striatal NMDA receptor subunits associated with the development of dyskinesia in the MPTP-
lesioned primate model of Parkinson’s disease. Neuropharmacology 48, 503–516, https://doi.org/10.1016/j.neuropharm.2004.11.008 
(2005).
 11. Johnson, K. A., Conn, P. J. & Niswender, C. M. Glutamate receptors as therapeutic targets for Parkinson’s disease. CNS Neurol Disord 
Drug Targets 8, 475–491 (2009).
 12. Calabresi, P. et al. New synaptic and molecular targets for neuroprotection in Parkinson’s disease. Mov Disord 28, 51–60, https://doi.
org/10.1002/mds.25096 (2013).
 13. Hallett, P. J. & Standaert, D. G. Rationale for and use of NMDA receptor antagonists in Parkinson’s disease. Pharmacol Ther 102, 
155–174, https://doi.org/10.1016/j.pharmthera.2004.04.001 (2004).
 14. Martineau, M., Baux, G. & Mothet, J. P. D-serine signalling in the brain: friend and foe. Trends Neurosci 29, 481–491, https://doi.
org/10.1016/j.tins.2006.06.008 (2006).
 15. Wolosker, H., Balu, D. T. & Coyle, J. T. The Rise and Fall of the d-Serine-Mediated Gliotransmission Hypothesis. Trends Neurosci 39, 
712–721, https://doi.org/10.1016/j.tins.2016.09.007 (2016).
 16. Errico, F., Nuzzo, T., Carella, M., Bertolino, A. & Usiello, A. The Emerging Role of Altered d-Aspartate Metabolism in Schizophrenia: 
New Insights From Preclinical Models and Human Studies. Front Psychiatry 9, 559, https://doi.org/10.3389/fpsyt.2018.00559 (2018).
 17. Salvatore, F., Zappia, V. & Cortese, R. Studies on the deamination of L-amino acids in mammalian tissues. Enzymologia 31, 113–127 
(1966).
 18. Salvatore, F. & Bocchini, V. Prevention of ammonia toxicity by amino-acids concerned in the biosynthesis of urea. Nature 191, 
705–706 (1961).
 19. Herring, B. E., Silm, K., Edwards, R. H. & Nicoll, R. A. Is Aspartate an Excitatory Neurotransmitter? J Neurosci 35, 10168–10171, 
https://doi.org/10.1523/JNEUROSCI.0524-15.2015 (2015).
 20. Pollegioni, L. & Sacchi, S. Metabolism of the neuromodulator D-serine. Cell Mol Life Sci 67, 2387–2404, https://doi.org/10.1007/
s00018-010-0307-9 (2010).
 21. Wolosker, H. et al. Purification of serine racemase: biosynthesis of the neuromodulator D-serine. Proc Natl Acad Sci USA 96, 
721–725 (1999).
 22. Murtas, G., Sacchi, S., Valentino, M. & Pollegioni, L. Biochemical Properties of Human D-Amino Acid Oxidase. Front Mol Biosci 4, 
88, https://doi.org/10.3389/fmolb.2017.00088 (2017).
 23. Sacchi, S., Caldinelli, L., Cappelletti, P., Pollegioni, L. & Molla, G. Structure-function relationships in human D-amino acid oxidase. 
Amino Acids 43, 1833–1850, https://doi.org/10.1007/s00726-012-1345-4 (2012).
 24. Katane, M. & Homma, H. D-aspartate oxidase: the sole catabolic enzyme acting on free D-aspartate in mammals. Chem Biodivers 7, 
1435–1449, https://doi.org/10.1002/cbdv.200900250 (2010).
 25. El Arfani, A. et al. Alterations in the motor cortical and striatal glutamatergic system and D-serine levels in the bilateral 
6-hydroxydopamine rat model for Parkinson’s disease. Neurochem Int 88, 88–96, https://doi.org/10.1016/j.neuint.2015.07.005 
(2015).
 26. Li, S., Yu, Q., Lu, X. & Zhao, S. Determination of D,L-serine in midbrain of Parkinson’s disease mouse by capillary electrophoresis 
with in-column light-emitting diode induced fluorescence detection. J Sep Sci 32, 282–287, https://doi.org/10.1002/jssc.200800459 
(2009).
 27. Lu, M. et al. Potentiation of D-serine involves degeneration of dopaminergic neurons in MPTP/p mouse model of Parkinson’s 
disease. CNS Neurosci Ther 17, 796–798, https://doi.org/10.1111/j.1755-5949.2011.00275.x (2011).
 28. Gelfin, E. et al. D-serine adjuvant treatment alleviates behavioural and motor symptoms in Parkinson’s disease. Int J 
Neuropsychopharmacol 15, 543–549, https://doi.org/10.1017/S1461145711001015 (2012).
 29. Tsai, C. H. et al. Activation of N-methyl-D-aspartate receptor glycine site temporally ameliorates neuropsychiatric symptoms of 
Parkinson’s disease with dementia. Psychiatry Clin Neurosci 68, 692–700, https://doi.org/10.1111/pcn.12175 (2014).
 30. Punzo, D. et al. Age-Related Changes in D-Aspartate Oxidase Promoter Methylation Control Extracellular D-Aspartate Levels and 
Prevent Precocious Cell Death during Brain Aging. J Neurosci 36, 3064–3078, https://doi.org/10.1523/JNEUROSCI.3881-15.2016 
(2016).
1 4Scientific RepoRts |          (2019) 9:8898  | https://doi.org/10.1038/s41598-019-45419-1
www.nature.com/scientificreportswww.nature.com/scientificreports/
 31. Errico, F. et al. Higher free D-aspartate and N-methyl-D-aspartate levels prevent striatal depotentiation and anticipate L-DOPA-
induced dyskinesia. Exp Neurol 232, 240–250, https://doi.org/10.1016/j.expneurol.2011.09.013 (2011).
 32. Deumens, R., Blokland, A. & Prickaerts, J. Modeling Parkinson’s disease in rats: an evaluation of 6-OHDA lesions of the nigrostriatal 
pathway. Exp Neurol 175, 303–317, https://doi.org/10.1006/exnr.2002.7891 (2002).
 33. Porras, G., Li, Q. & Bezard, E. Modeling Parkinson’s disease in primates: The MPTP model. Cold Spring Harb Perspect Med 2, 
a009308, https://doi.org/10.1101/cshperspect.a009308 (2012).
 34. Engeln, M., De Deurwaerdere, P., Li, Q., Bezard, E. & Fernagut, P. O. Widespread Monoaminergic Dysregulation of Both Motor and 
Non-Motor Circuits in Parkinsonism and Dyskinesia. Cereb Cortex 25, 2783–2792, https://doi.org/10.1093/cercor/bhu076 (2015).
 35. Porras, G. et al. L-dopa-induced dyskinesia: beyond an excessive dopamine tone in the striatum. Sci Rep 4, 3730, https://doi.
org/10.1038/srep03730 (2014).
 36. Chouinard, M. L., Gaitan, D. & Wood, P. L. Presence of the N-methyl-D-aspartate-associated glycine receptor agonist, D-serine, in 
human temporal cortex: comparison of normal, Parkinson, and Alzheimer tissues. J Neurochem 61, 1561–1564 (1993).
 37. Talati, A. & Hirsch, J. Functional specialization within the medial frontal gyrus for perceptual go/no-go decisions based on “what,” 
“when,” and “where” related information: an fMRI study. J Cogn Neurosci 17, 981–993, https://doi.org/10.1162/0898929054475226 
(2005).
 38. Sasabe, J., Suzuki, M., Imanishi, N. & Aiso, S. Activity of D-amino acid oxidase is widespread in the human central nervous system. 
Front Synaptic Neurosci 6, 14, https://doi.org/10.3389/fnsyn.2014.00014 (2014).
 39. Calon, F. et al. Alteration of glutamate receptors in the striatum of dyskinetic 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated 
monkeys following dopamine agonist treatment. Prog Neuropsychopharmacol Biol Psychiatry 26, 127–138 (2002).
 40. Morin, N. et al. Chronic treatment with MPEP, an mGlu5 receptor antagonist, normalizes basal ganglia glutamate neurotransmission 
in L-DOPA-treated parkinsonian monkeys. Neuropharmacology 73, 216–231, https://doi.org/10.1016/j.neuropharm.2013.05.028 
(2013).
 41. Mellone, M. et al. NMDA receptor GluN2A/GluN2B subunit ratio as synaptic trait of levodopa-induced dyskinesias: from 
experimental models to patients. Front Cell Neurosci 9, 245, https://doi.org/10.3389/fncel.2015.00245 (2015).
 42. Silverdale, M. A. et al. Synaptic recruitment of AMPA glutamate receptor subunits in levodopa-induced dyskinesia in the MPTP-
lesioned nonhuman primate. Synapse 64, 177–180, https://doi.org/10.1002/syn.20739 (2010).
 43. Yung, K. K. Localization of ionotropic and metabotropic glutamate receptors in distinct neuronal elements of the rat substantia 
nigra. Neurochem Int 33, 313–326 (1998).
 44. Gardoni, F. & Di Luca, M. Targeting glutamatergic synapses in Parkinson’s disease. Curr Opin Pharmacol 20, 24–28, https://doi.
org/10.1016/j.coph.2014.10.011 (2015).
 45. Paille, V. et al. Distinct levels of dopamine denervation differentially alter striatal synaptic plasticity and NMDA receptor subunit 
composition. J Neurosci 30, 14182–14193, https://doi.org/10.1523/JNEUROSCI.2149-10.2010 (2010).
 46. Sgambato-Faure, V. & Cenci, M. A. Glutamatergic mechanisms in the dyskinesias induced by pharmacological dopamine 
replacement and deep brain stimulation for the treatment of Parkinson’s disease. Prog Neurobiol 96, 69–86, https://doi.org/10.1016/j.
pneurobio.2011.10.005 (2012).
 47. Heresco-Levy, U., Shoham, S. & Javitt, D. C. Glycine site agonists of the N-methyl-D-aspartate receptor and Parkinson’s disease: a 
hypothesis. Mov Disord 28, 419–424, https://doi.org/10.1002/mds.25306 (2013).
 48. Cheramy, A., L’Hirondel, M., Godeheu, G., Artaud, F. & Glowinski, J. Direct and indirect presynaptic control of dopamine release by 
excitatory amino acids. Amino Acids 14, 63–68 (1998).
 49. Shimizu, S. et al. Glycine-Binding Site Stimulants of NMDA Receptors Alleviate Extrapyramidal Motor Disorders by Activating the 
Nigrostriatal Dopaminergic Pathway. Int J Mol Sci 18 https://doi.org/10.3390/ijms18071416 (2017).
 50. Hansen, K. B. et al. Structure, function, and allosteric modulation of NMDA receptors. J Gen Physiol 150, 1081–1105, https://doi.
org/10.1085/jgp.201812032 (2018).
 51. Zhou, X., Chen, Z., Yun, W. & Wang, H. NMDA receptor activity determines neuronal fate: location or number? Rev Neurosci 26, 
39–47, https://doi.org/10.1515/revneuro-2014-0053 (2015).
 52. Kantrowitz, J. T. et al. High dose D-serine in the treatment of schizophrenia. Schizophr Res 121, 125–130, https://doi.org/10.1016/j.
schres.2010.05.012 (2010).
 53. Hsu, W. Y., Lane, H. Y. & Lin, C. H. Medications Used for Cognitive Enhancement in Patients With Schizophrenia, Bipolar Disorder, 
Alzheimer’s Disease, and Parkinson’s Disease. Front Psychiatry 9, 91, https://doi.org/10.3389/fpsyt.2018.00091 (2018).
 54. Fagg, G. E. & Matus, A. Selective association of N-methyl aspartate and quisqualate types of L-glutamate receptor with brain 
postsynaptic densities. Proc Natl Acad Sci USA 81, 6876–6880 (1984).
 55. Mothet, J. P. et al. D-serine is an endogenous ligand for the glycine site of the N-methyl-D-aspartate receptor. Proc Natl Acad Sci USA 
97, 4926–4931 (2000).
 56. Patneau, D. K. & Mayer, M. L. Structure-activity relationships for amino acid transmitter candidates acting at N-methyl-D-aspartate 
and quisqualate receptors. J Neurosci 10, 2385–2399 (1990).
 57. Solis, O., Garcia-Sanz, P., Herranz, A. S., Asensio, M. J. & Moratalla, R. L-DOPA Reverses the Increased Free Amino Acids Tissue 
Levels Induced by Dopamine Depletion and Rises GABA and Tyrosine in the Striatum. Neurotox Res 30, 67–75, https://doi.
org/10.1007/s12640-016-9612-x (2016).
 58. Horio, M. et al. Decreased levels of free D-aspartic acid in the forebrain of serine racemase (Srr) knock-out mice. Neurochem Int 62, 
843–847, https://doi.org/10.1016/j.neuint.2013.02.015 (2013).
 59. Ito, T. et al. Serine racemase is involved in d-aspartate biosynthesis. J Biochem. https://doi.org/10.1093/jb/mvw043 (2016).
 60. Park, H. K. et al. Potential role for astroglial D-amino acid oxidase in extracellular D-serine metabolism and cytotoxicity. J Biochem 
139, 295–304, https://doi.org/10.1093/jb/mvj036 (2006).
 61. Verrall, L. et al. d-Amino acid oxidase and serine racemase in human brain: normal distribution and altered expression in 
schizophrenia. Eur J Neurosci 26, 1657–1669, https://doi.org/10.1111/j.1460-9568.2007.05769.x (2007).
 62. Awad, H., Hubert, G. W., Smith, Y., Levey, A. I. & Conn, P. J. Activation of metabotropic glutamate receptor 5 has direct excitatory 
effects and potentiates NMDA receptor currents in neurons of the subthalamic nucleus. J Neurosci 20, 7871–7879, doi:20/21/7871 
[pii] (2000).
 63. Marino, M. J., Valenti, O. & Conn, P. J. Glutamate receptors and Parkinson’s disease: opportunities for intervention. Drugs Aging 20, 
377–397, doi:2056 [pii] (2003).
 64. Waxman, E. A. & Lynch, D. R. N-methyl-D-aspartate receptor subtypes: multiple roles in excitotoxicity and neurological disease. 
Neuroscientist 11, 37–49, https://doi.org/10.1177/1073858404269012 (2005).
 65. Sasabe, J. et al. D-serine is a key determinant of glutamate toxicity in amyotrophic lateral sclerosis. EMBO J 26, 4149–4159, https://
doi.org/10.1038/sj.emboj.7601840 (2007).
 66. Bourdenx, M. et al. Abnormal structure-specific peptide transmission and processing in a primate model of Parkinson’s disease and 
l-DOPA-induced dyskinesia. Neurobiol Dis 62, 307–312, https://doi.org/10.1016/j.nbd.2013.10.016 (2014).
 67. Charron, G. et al. Endogenous morphine-like compound immunoreactivity increases in parkinsonism. Brain 134, 2321–2338, 
https://doi.org/10.1093/brain/awr166 (2011).
 68. Napolitano, F. et al. Decreased Rhes mRNA levels in the brain of patients with Parkinson’s disease and MPTP-treated macaques. 
PLoS One 12, e0181677, https://doi.org/10.1371/journal.pone.0181677 (2017).
1 5Scientific RepoRts |          (2019) 9:8898  | https://doi.org/10.1038/s41598-019-45419-1
www.nature.com/scientificreportswww.nature.com/scientificreports/
 69. Porras, G. et al. PSD-95 expression controls L-DOPA dyskinesia through dopamine D1 receptor trafficking. J Clin Invest 122, 
3977–3989, https://doi.org/10.1172/JCI59426 (2012).
 70. Rojo-Bustamante, E. et al. The expression of cannabinoid type 1 receptor and 2-arachidonoyl glycerol synthesizing/degrading 
enzymes is altered in basal ganglia during the active phase of levodopa-induced dyskinesia. Neurobiol Dis 118, 64–75, https://doi.
org/10.1016/j.nbd.2018.06.019 (2018).
 71. Santini, E. et al. Distinct changes in cAMP and extracellular signal-regulated protein kinase signalling in L-DOPA-induced 
dyskinesia. PLoS One 5, e12322, https://doi.org/10.1371/journal.pone.0012322 (2010).
 72. Shariatgorji, M. et al. Direct targeted quantitative molecular imaging of neurotransmitters in brain tissue sections. Neuron 84, 
697–707, https://doi.org/10.1016/j.neuron.2014.10.011 (2014).
 73. Stanic, J. et al. Rabphilin 3A: A novel target for the treatment of levodopa-induced dyskinesias. Neurobiol Dis 108, 54–64, https://doi.
org/10.1016/j.nbd.2017.08.001 (2017).
 74. Hughes, A. J., Daniel, S. E., Kilford, L. & Lees, A. J. Accuracy of clinical diagnosis of idiopathic Parkinson’s disease: a clinico-
pathological study of 100 cases. J Neurol Neurosurg Psychiatry 55, 181–184 (1992).
 75. Litvan, I. et al. Movement Disorders Society Scientific Issues Committee report: SIC Task Force appraisal of clinical diagnostic 
criteria for Parkinsonian disorders. Mov Disord 18, 467–486, https://doi.org/10.1002/mds.10459 (2003).
 76. del Campo, M. et al. Recommendations to standardize preanalytical confounding factors in Alzheimer’s and Parkinson’s disease 
cerebrospinal fluid biomarkers: an update. Biomark Med 6, 419–430, https://doi.org/10.2217/bmm.12.46 (2012).
 77. Devoto, P. et al. 6-Hydroxydopamine lesion in the ventral tegmental area fails to reduce extracellular dopamine in the cerebral 
cortex. J Neurosci Res 86, 1647–1658, https://doi.org/10.1002/jnr.21611 (2008).
 78. Nuzzo, T. et al. Decreased free d-aspartate levels are linked to enhanced d-aspartate oxidase activity in the dorsolateral prefrontal 
cortex of schizophrenia patients. NPJ Schizophr 3, 16, https://doi.org/10.1038/s41537-017-0015-7 (2017).
Acknowledgements
AU was supported by a grant from Fondazione Cariplo.
Author Contributions
T.N. performed HPLC analyses of amino acids and western blotting; D.P. performed quantitative real-time PCR 
studies; P.D. performed HPLC analyses of dopamine and DOPAC under M.C. supervision, M.C. edited the 
manuscript; E.R., S.S. and L.Po. set up in vitro enzymatic assays, interpreted data and edited the manuscript; S.P., 
P.C. and L.Pa. provided human samples, interpreted results and edited the manuscript; L.Q., M.L.T., C.V. and E.B. 
provided monkeys samples and interpreted results, E.B. edited the manuscript; M.C. helped to interpret results; 
F.G. helped to interpret results and contributed to writing the manuscript; A.U. and F.E. conceived the work and 
wrote the manuscript.
Additional Information
Supplementary information accompanies this paper at https://doi.org/10.1038/s41598-019-45419-1.
Competing Interests: The authors declare no competing interests.
Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and 
institutional affiliations.
Open Access This article is licensed under a Creative Commons Attribution 4.0 International 
License, which permits use, sharing, adaptation, distribution and reproduction in any medium or 
format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Cre-
ative Commons license, and indicate if changes were made. The images or other third party material in this 
article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the 
material. If material is not included in the article’s Creative Commons license and your intended use is not per-
mitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the 
copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
 
© The Author(s) 2019
